http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Jul 2026 08:02:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/IN8bio+publishes+Phase+1+glioblastoma+trial+data+in+oncology+journal/26750477.html <p>IN8bio, Inc. (Nasdaq: INAB) announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in <em>The Journal of Clinical Oncology</em>, reporting results from a first-in-human study of its DeltEx Drug Resistant Immunotherapy (DRI) in patients with newly diagnosed glioblastoma (GBM).</p><p>The Phase 1 frequency-escalation study enrolled 13 patients across three cohorts receiving one, three, or up to six doses of DeltEx DRI in 28-day cycles during maintenance chemotherapy, in combination with the standard of care Stupp regimen. DeltEx DRI consists of autologous gamma-delta T cells genetically engineered to resist alkylating chemotherapy and delivered intracranially to the tumor http://www.streetinsider.com/Corporate+News/IN8bio+publishes+Phase+1+glioblastoma+trial+data+in+oncology+journal/26750477.html Thu, 09 Jul 2026 08:02:40 -0400 INAB http://www.streetinsider.com/FDA/IN8bio+publishes+Phase+1+glioblastoma+trial+data+in+oncology+journal/26750477.html <p>IN8bio, Inc. (Nasdaq: INAB) announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in <em>The Journal of Clinical Oncology</em>, reporting results from a first-in-human study of its DeltEx Drug Resistant Immunotherapy (DRI) in patients with newly diagnosed glioblastoma (GBM).</p><p>The Phase 1 frequency-escalation study enrolled 13 patients across three cohorts receiving one, three, or up to six doses of DeltEx DRI in 28-day cycles during maintenance chemotherapy, in combination with the standard of care Stupp regimen. DeltEx DRI consists of autologous gamma-delta T cells genetically engineered to resist alkylating chemotherapy and delivered intracranially to the tumor http://www.streetinsider.com/FDA/IN8bio+publishes+Phase+1+glioblastoma+trial+data+in+oncology+journal/26750477.html Thu, 09 Jul 2026 08:02:40 -0400 INAB http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html <ul><li style="text-align:left;"><em>First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma</em><br/></li></ul> <ul><li><em>Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)</em><br/><br/></li></ul> <p align="left">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JMSCtp__vJ3x6zA2W7l6cUXUTA3_9hGe3MSkC9BDR8T65C9AdN6BOnqulb__R6Yp_jzNkeIdwZHtpWdxHuNLww==" rel="nofollow" target="_blank">IN8bio, Inc.</a> (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+The+Journal+of+Clinical+Oncology+Demonstrating+DeltEx%E2%84%A2+DRI+Doubles+Progression-Free+Survival+in+Newly+Diagnosed+Glioblastoma/26750397.html Thu, 09 Jul 2026 08:00:00 -0400 A.41370723 A.50209015 INAB O.00225875 O.22007091 O.49100899 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+IN8bio+Inc.+%28INAB%29/26602163.html <p>H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $6.00 price target on IN8bio Inc. (NASDAQ: INAB).</p><p>The analyst commented: "At the 2026 annual meeting of ASCO, IN8bio provided consolidated data from 17 patients who enrolled into Phase 1 INB-200 and Phase 2 INB-400 studies evaluating the DeltEx DRI gamma-delta (γδ) T-cell therapy as a treatment for newly diagnosed glioblastoma (GBM) patients. The repeat-dose cohort (n=14) experienced a median progression-free survival (mPFS) of 13.0 months, nearly double the 6.6 months achieved by the standard of care (SOC) arm. Regarding overall survival, while the repeat-dose cohort is yet to achieve a http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+IN8bio+Inc.+%28INAB%29/26602163.html Thu, 04 Jun 2026 06:44:20 -0400 INAB http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Press+Releases/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=Gl8nFHVHCrDdxw6N9pwiWsqcp2uT2TcdZufvAEod1KIpByoLjZyDu_wkaXN6seHQzzC5qEd_bGnJRQmGCKYynktXAN61DqiECA_60HUOR4AbgFz6ItY89__wMLZq5MlDQRodAigPe9gbznujwtUsiBy4AAPdNUjLYQJKGFFR_K8s4kKgwbBDHxG59jhhZl7RllwGgnXeae2bmxbgfdF9dw==" rel="nofollow" target="_blank">Harnessing γδ T cells through engineering and combination therapies</a>” in the journal <em>Nature Communications</em>. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors http://www.streetinsider.com/Globe+Newswire/IN8bio+Announces+Publication+in+Nature+Communications+Highlighting+Advances+in+Gamma-Delta+T+Cell+Engineering+and+Combination+Therapies/26595930.html Wed, 03 Jun 2026 08:30:00 -0400 A.31293549 INAB O.00573636 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Presents+Updated+Overall+Survival+Data+Surpassing+19.5+Months+for+DeltEx+DRI+in+Newly+Diagnosed+Glioblastoma+at+ASCO+2026/26579823.html <p style="padding-left:40px;"><em>Repeat dosing of DeltEx</em><em>TM</em><em> Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).</em></p> <p style="padding-left:40px;"><em>Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years. </em></p> <p>NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=iSdcAyuY0DVGPclG92W6cPrMO9X_Kxl5nf7VP_E8qeyUEnQj2oso1Y3vqY8lRZfsycHEVBLxeqMiNJb60V6D_8sCX8_XluSPsngeqFgJeVo0nAwYH2Xa6U7JCb2SvVDADdvb7jRQH8QYbz2XkT8naZIKWGEVwqJKNcoqoEA6VV4rvGdK83kp-Akkd4Fjkt_gh2a6ZW1cXUqMpTYQjwZhONrdaVZYsZEweTMk536d5cs=" rel="nofollow" target="_blank">IN8bio</a>, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and http://www.streetinsider.com/Press+Releases/IN8bio+Presents+Updated+Overall+Survival+Data+Surpassing+19.5+Months+for+DeltEx+DRI+in+Newly+Diagnosed+Glioblastoma+at+ASCO+2026/26579823.html Mon, 01 Jun 2026 08:30:00 -0400 A.50216726 INAB O.21612337 O.49100899 http://www.streetinsider.com/Press+Releases/IN8bio+Presents+Updated+Overall+Survival+Data+Surpassing+19.5+Months+for+DeltEx+DRI+in+Newly+Diagnosed+Glioblastoma+at+ASCO+2026/26579823.html <p style="padding-left:40px;"><em>Repeat dosing of DeltEx</em><em>TM</em><em> Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).</em></p> <p style="padding-left:40px;"><em>Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years. </em></p> <p>NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=iSdcAyuY0DVGPclG92W6cPrMO9X_Kxl5nf7VP_E8qeyUEnQj2oso1Y3vqY8lRZfsycHEVBLxeqMiNJb60V6D_8sCX8_XluSPsngeqFgJeVo0nAwYH2Xa6U7JCb2SvVDADdvb7jRQH8QYbz2XkT8naZIKWGEVwqJKNcoqoEA6VV4rvGdK83kp-Akkd4Fjkt_gh2a6ZW1cXUqMpTYQjwZhONrdaVZYsZEweTMk536d5cs=" rel="nofollow" target="_blank">IN8bio</a>, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and http://www.streetinsider.com/Press+Releases/IN8bio+Presents+Updated+Overall+Survival+Data+Surpassing+19.5+Months+for+DeltEx+DRI+in+Newly+Diagnosed+Glioblastoma+at+ASCO+2026/26579823.html Mon, 01 Jun 2026 08:30:00 -0400 A.50216726 INAB O.21612337 O.49100899